Last reviewed · How we verify

Docetaxel/capecitabine followed by XEC

China Breast Cancer Clinical Study Group · Phase 3 active Small molecule

Docetaxel/capecitabine followed by XEC is a Chemotherapy combination regimen Small molecule drug developed by China Breast Cancer Clinical Study Group. It is currently in Phase 3 development for Breast cancer (neoadjuvant or adjuvant setting). Also known as: Capecitabine: Xeloda.

This regimen combines docetaxel (a microtubule-stabilizing chemotherapy) and capecitabine (a fluoropyrimidine prodrug) followed by XEC (a combination of cyclophosphamide, epirubicin, and 5-fluorouracil) to inhibit cancer cell division and induce apoptosis.

This regimen combines docetaxel (a microtubule-stabilizing chemotherapy) and capecitabine (a fluoropyrimidine prodrug) followed by XEC (a combination of cyclophosphamide, epirubicin, and 5-fluorouracil) to inhibit cancer cell division and induce apoptosis. Used for Breast cancer (neoadjuvant or adjuvant setting).

At a glance

Generic nameDocetaxel/capecitabine followed by XEC
Also known asCapecitabine: Xeloda
SponsorChina Breast Cancer Clinical Study Group
Drug classChemotherapy combination regimen
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Docetaxel stabilizes microtubules and prevents their disassembly, halting mitosis in cancer cells. Capecitabine is converted to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis. The XEC regimen delivers additional chemotherapy agents with complementary mechanisms: cyclophosphamide alkylates DNA, epirubicin intercalates DNA and generates reactive oxygen species, and 5-fluorouracil again targets nucleotide synthesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Docetaxel/capecitabine followed by XEC

What is Docetaxel/capecitabine followed by XEC?

Docetaxel/capecitabine followed by XEC is a Chemotherapy combination regimen drug developed by China Breast Cancer Clinical Study Group, indicated for Breast cancer (neoadjuvant or adjuvant setting).

How does Docetaxel/capecitabine followed by XEC work?

This regimen combines docetaxel (a microtubule-stabilizing chemotherapy) and capecitabine (a fluoropyrimidine prodrug) followed by XEC (a combination of cyclophosphamide, epirubicin, and 5-fluorouracil) to inhibit cancer cell division and induce apoptosis.

What is Docetaxel/capecitabine followed by XEC used for?

Docetaxel/capecitabine followed by XEC is indicated for Breast cancer (neoadjuvant or adjuvant setting).

Who makes Docetaxel/capecitabine followed by XEC?

Docetaxel/capecitabine followed by XEC is developed by China Breast Cancer Clinical Study Group (see full China Breast Cancer Clinical Study Group pipeline at /company/china-breast-cancer-clinical-study-group).

Is Docetaxel/capecitabine followed by XEC also known as anything else?

Docetaxel/capecitabine followed by XEC is also known as Capecitabine: Xeloda.

What drug class is Docetaxel/capecitabine followed by XEC in?

Docetaxel/capecitabine followed by XEC belongs to the Chemotherapy combination regimen class. See all Chemotherapy combination regimen drugs at /class/chemotherapy-combination-regimen.

What development phase is Docetaxel/capecitabine followed by XEC in?

Docetaxel/capecitabine followed by XEC is in Phase 3.

What are the side effects of Docetaxel/capecitabine followed by XEC?

Common side effects of Docetaxel/capecitabine followed by XEC include Neutropenia, Anemia, Thrombocytopenia, Nausea and vomiting, Diarrhea, Hand-foot syndrome.

Related